Results 231 to 240 of about 244,603 (309)

Qualitative analysis of genomic mutations and antibiotic susceptibility testing of Pseudomonas aeruginosa isolates from chronic lung infections. [PDF]

PLoS One
Fluit AC, Bayjanov JR, Aguilar MD, Cantón R, Gilpin DF, Tunney MM, Ekkelenkamp MB.   +6 more
europepmc   +1 more source

Immunoinformatics‐Based Design of a Multi‐Epitope Vaccine Targeting a Conserved Copper–Associated Protein in Neisseria gonorrhoeae

Biotechnology and Applied Biochemistry, EarlyView.
ABSTRACT Neisseria gonorrhoeae poses an urgent public health challenge due to rapidly increasing antimicrobial resistance and the absence of an effective vaccine. Targeting conserved bacterial pathways involved in essential physiological processes may provide new opportunities for vaccine antigen discovery.
Sinethemba H. Yakobi, Uchechukwu U. Nwodo   +1 more
wiley   +1 more source

Next generation sequencing as a panacea for antibiotic susceptibility testing: yea or nay? [PDF]

Front Public Health
van Belkum A.
europepmc   +1 more source

A systematic scoping review of metrics utilized to measure antibiotic consumption in hospital settings

British Journal of Clinical Pharmacology, EarlyView.
Abstract Antimicrobial stewardship (AMS) programs were introduced to promote the judicious use of antimicrobials and to combat antimicrobial resistance. Quantifying antibiotic consumption is an important part of AMS initiatives to achieve these objectives.
Marjan Kandimahforoujaki, Kiplin A. Patanwala, Jan‐Willem C. Alffenaar, Asad E. Patanwala   +3 more
wiley   +1 more source

Comparison of <i>in vitro</i> antibiotic susceptibility testing of <i>R. typhi</i> using plaque assay and quantitative real-time PCR. [PDF]

Microbiol Spectr
Phuklia W, Padith K, Farris CM, Richards AL, Phommasone K, Mayxay M, Mukaka M, Robinson MT, Newton PN, Day NPJ, Ashley EA.   +10 more
europepmc   +1 more source

Population pharmacokinetics of levofloxacin in breastmilk in patients with rifampicin‐resistant tuberculosis

British Journal of Clinical Pharmacology, EarlyView.
Levofloxacin is a widely used antibiotic included in rifampicin‐resistant tuberculosis (RR‐TB) treatment. Data describing levofloxacin concentrations in breastmilk and infant exposure are limited. We analysed data from two South African studies of breastfeeding women receiving levofloxacin (750–1000 mg daily) for RR‐TB.
Sharon Sawe, Lufina Tsirizani, Buyisile Mkhize, Lubbe Wiesner, Gary Maartens, Francesca Conradie, Richard Court, Marian Loveday, Catriona Waitt, Paolo Denti   +9 more
wiley   +1 more source

Nanomotion-enabled ultra-rapid antibiotic susceptibility testing with magnetic bead-based pathogen enrichment for accelerated sepsis diagnostics. [PDF]

Sci Rep
Jóźwiak G, Pla Verge M, Luraschi-Eggemann A, Mestiri C, McSorley E, Wilson-Owen D, La Fauci S, García-Castillo M, Delarze E, Fromm K, Munch L, Vogel C, Balasopoulos D, Cathomen G, Reiter S, Świątkowski M, Totu R, Häussler S, Tenson T, Pagliara S, Cantón R, Greub G, Lisby G, Mullen W, Lockhart D, Cichocka D, Sturm A, ERADIAMR consortium.   +27 more
europepmc   +1 more source

Active surveillance of drug safety in healthcare data: Sequential monitoring of bacterial and serious urinary tract infection risk in sodium‐glucose cotransporter 2 inhibitor users

British Journal of Clinical Pharmacology, EarlyView.
Abstract Introduction Active surveillance of adverse events using healthcare data is emerging as complementary to the monitoring of spontaneous reports and stand‐alone pharmacoepidemiologic studies. The risk of urinary tract infections (UTIs) was listed as a special warning for sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) when marketed in Europe
Haoxin Le, Dilsad Simay Peker, Lukas Frederic Westphal, Nikolai Brun, Christine Erikstrup Hallgreen, Morten Andersen   +5 more
wiley   +1 more source

Involvement of HemI, an ECF sigma factor, in hemin acquisition and antibiotic susceptibility in <i>Stenotrophomonas maltophilia</i>. [PDF]

Front Cell Infect Microbiol
Liao CH, Ku RH, Lu HF, Hu EW, Li LH, Yang TC.   +5 more
europepmc   +1 more source

S. aureus colonization and clinical symptoms remain stable upon topical XZ.700 treatment: Results of a double‐blind randomized clinical trial in patients with mild to moderate atopic dermatitis

British Journal of Clinical Pharmacology, EarlyView.
Aim Recovering dysbiosis may improve atopic dermatitis (AD) symptoms. XZ.700 is a recombinant chimeric endolysin that specifically targets Staphylococcus aureus and could be a new treatment option for patients with AD. The aim of this first‐in‐human study was to evaluate the safety, tolerability and efficacy of topical XZ.700 and explore the ...
Laura W. J. van der Meulen, Menthe E. Bergmans, Salma Assil, Naomi Klarenbeek, Marieke L. de Kam, Alexa J. Tibboel, Thorsten Brach, Bjorn L. Herpers, Johan Frieling, Vincent de Jong, Benthe Freyee, Martijn B. A. van Doorn, Robert Rissmann, Tessa Niemeyer–van der Kolk   +13 more
wiley   +1 more source